◆英語タイトル:Numab Innovation AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10675
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Numab Innovation AG (Numab) is a developer of novel therapeutics for the treatment of severe diseases. The company’s pipeline products include ND007, ND009, ND016, ND017, ND023, ND026, and ND021. Its ND007 is a bispecific antibody fragment which is being evaluated for the treatment of autoimmune diseases. Numab’s ND009 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease, a chronic inflammation of the digestive tract that includes ulcerative colitis and Crohn’s disease. The company’s products are used in the treatment of inflammatory bowel disease, autoimmune disorders and metabolic disorders. It utilizes a proprietary antibody discovery and engineering technology to produce antibody Fv fragments. Numab is headquartered in Wadenswil, Switzerland.
Numab Innovation AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Numab Innovation AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Numab Innovation AG, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Numab Acquires ND003 From Sucampo 10
Venture Financing 11
Numab To Raise Funds Through Series A Financing 11
Partnerships 12
Numab Therapeutics Enters into Research and Option Agreement with Kaken Pharma 12
Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 13
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 14
Licensing Agreements 15
Tillotts Pharma Enters into Licensing Agreement with Numab 15
Numab Innovation AG – Key Competitors 16
Numab Innovation AG – Key Employees 17
Numab Innovation AG – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19
List of Tables
Numab Innovation AG, Pharmaceuticals & Healthcare, Key Facts 2
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Numab Innovation AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Numab Innovation AG, Deals By Therapy Area, 2012 to YTD 2018 8
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Numab Acquires ND003 From Sucampo 10
Numab To Raise Funds Through Series A Financing 11
Numab Therapeutics Enters into Research and Option Agreement with Kaken Pharma 12
Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 13
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 14
Tillotts Pharma Enters into Licensing Agreement with Numab 15
Numab Innovation AG, Key Competitors 16
Numab Innovation AG, Key Employees 17
Numab Innovation AG, Subsidiaries 18
List of Figures
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8